SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is trending as investors focus on uranium as the essential backbone for AI-driven energy demand, with ongoing community discussion centered on nuclear's role as a critical, long-term power source. Sentiment is further buoyed by major recent supply deals and consistent institutional rotation into the sector, with many traders looking for a breakout above key psychological resistance levels.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune is generating significant investor buzz following positive clinical trial data and the strategic expansion of its pipeline into migraine prophylaxis, a move that is reshaping the company's perception as a multi-therapeutic powerhouse. While some community members are focused on potential near-term catalysts and short-squeeze dynamics, others are actively debating the long-term efficacy of its drug candidates and the impact of executive stock activity.

SiTime Corp.is a micro-electromechanical system-based silicon timing solution. The company is transforming the timing industry with configurable solutions that replace legacy quartz devices and enable customers to differentiate their products with performance, smaller size, lower power, and reliability. The company was founded by Markus Lutz and Aaron Partridge on December 3, 2003 and is headquartered in Santa Clara, CA.

SiTime Corp

SiTime is trending as community members discuss its dominance in the precision timing market and its critical role in AI data center infrastructure. Investors are closely monitoring its volatile technical patterns and recent supply chain developments while debating the stock's valuation versus its long-term potential as a monopoly-like leader.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is experiencing heightened interest as part of a broader resurgence in privacy-focused tokens, with community members actively comparing it to Zcash and Monero while watching for potential breakouts. Traders are closely monitoring the asset's technical patterns and integration news, expressing optimism that increased volume and adoption will drive momentum despite recent market volatility.

NexGen Energy Ltd. engages in the acquisition, exploration and development of uranium properties. Its uranium project portfolio includes Arrow, South Arrow, Harpoon, Bow, IsoEnergy, SW1, SW2, SW3, and IsoEnergy properties. The company was founded by Leigh B. Curyer on March 8, 2011 and is headquartered in Vancouver, Canada.

NexGen Energy Ltd

NexGen Energy is trending as institutional and retail investors focus on the company's tier-one Rook I project, which is seen as a critical asset for addressing the tightening global uranium supply deficit. The community is actively discussing the stock's potential for federal permitting approval and its strategic value for meeting the surging power needs of AI data centers.

Flex Ltd. operates as a manufacturing services company. It delivers technology innovation, supply chain, and manufacturing solutions to diverse industries and end markets. The firm operates through the following segments: Integrated Technology Solutions (ITS), Regulated Manufacturing Solutions (RMS) and Cloud and Power Infrastructure (CPI). The Integrated Technology Solutions segment consists of Communications, including high speed networking, enterprise, and satellite communications systems Lifestyle, including premium products across commercial, home and personal product categories. The Regulated Manufacturing Solutions segment consists of Industrial, including mission-critical automation, energy, and industrial infrastructure, Automotive, including compute and power electronics platforms, and integrated systems, Healthcare, including regulated manufacturing for medical devices, drug delivery and equipment. The Cloud and Power Infrastructure segment consists of Cloud and Cooling, including integrated compute systems supporting power-dense digital infrastructure deployments, and advanced liquid cooling solutions supporting higher-density, power-intensive rack architectures, Power, utility and facility-level, including electrical infrastructure enabling reliable, scalable power delivery and high-density rack- and board-level power systems supporting power-intensive compute workloads. The company was founded by Joe McKenzie and Barbara-Ann McKenzie in 1969 and is headquartered in Austin, TX.

Flex Ltd

Flex Ltd. is gaining investor attention following its official inclusion in the S&P 500, a move expected to trigger significant passive fund inflows. The market is also actively debating the company's long-term potential as it shifts toward a specialized AI infrastructure focus, particularly ahead of a planned spin-off of its Cloud and Power Infrastructure business.

Viper Energy, Inc. engages in the acquisition of oil and natural gas properties. It owns, acquires, and exploits oil and natural gas properties in North America. The company was founded on September 18, 2013 and is headquartered in Midland, TX.

Viper Energy Inc - Ordinary Shares - Class A

Viper Energy Partners LP

Viper Energy Partners is trending as investors monitor its strategic Permian Basin position and recent merger activities against a backdrop of global energy supply concerns. The community is actively discussing the stock's dividend potential and the long-term impact of its expanded asset footprint within the energy sector.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Schrodinger Inc. is trending as investors debate the potential of its AI-driven drug discovery platform while navigating concerns over capital-intensive proprietary programs and near-term revenue transitions. Community sentiment remains polarized, with some highlighting the stock's significant long-term potential as a 'multi-bagger' in the AI biotech gold rush, while others focus on management frustrations and the company's persistent cash-burning model.

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment provides scanning devices, clinical applications, service capabilities, and digital solutions. The AVS segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The PCS segment specializes in providing medical devices, consumables, services, and digital solutions. The PDx segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded in 1892. It was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare Technologies Inc

GE HealthCare is currently trending after receiving FDA 510(k) clearance for its AI-powered MIM Contour ProtegeAI+ 2.0 software, designed to streamline radiation oncology treatment planning. The stock remains a key topic of community discussion as investors weigh the potential of AI-driven medical innovation against ongoing debates regarding the company's valuation and the broader defensive sector rotation.

S&P Global, Inc. engages in the provision of transparent and independent ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. It operates through the following segments: Market Intelligence, Ratings, Mobility, Indices, and Engineering Solutions. The Market Intelligence segment provides multi-asset-class data and analytics integrated with purpose-built workflow solutions. The Ratings segment is involved in credit ratings, research, and analytics, offering investors and other market participants information, ratings, and benchmarks. The Mobility segment offers solutions serving the full automotive value chain including vehicle manufacturers, automotive suppliers, mobility service providers, retailers, consumers, and finance and insurance companies. The Engineering Solutions segment engages in advanced knowledge discovery technologies, research tools, and software-based engineering decision engines to advance innovation, maximize productivity, improve quality, and reduce risk. The company was founded by James H. McGraw and John A. Hill in 1917 and is headquartered in New York, NY.

S&P Global Inc

S&P Global is trending as investors rotate into high-quality, wide-moat compounders that are currently trading at significant discounts near 52-week lows. The community is actively debating the stock's long-term value, with many viewing the ongoing valuation contraction as a prime entry point for long-horizon capital while also monitoring the upcoming Mobility division spin-off as a key strategic catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.

J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

J&J's Pipeline Progress & New Drugs Promise Stronger Long-Term Growth 

J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst Says

Wedbush upped their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an 'outperform' rating in a research report on Wednesday...

Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.70. The company had revenue of $56.37 million for the quarter, compared to...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has received an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a ho...

331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC

Jennison Associates LLC bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 331,164 shares of the company's stock, v...

M&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX

M&T Bank Corp acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,207 shares of the company's stock, valued at approximately $979,000. Other large investors ha...

Pictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX

Pictet Asset Management Holding SA lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 529,631 shares o...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

PTGXProtagonist Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PTGX News